NAM
NKTR icon

Nexpoint Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Nexpoint Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,667
Closed -$718K – 227
2021
Q3 		$718K Sell
2,667
-333
-11% -$80.1K 0.12% 82
2021
Q2 		$772K Buy
3,000
+2,333
+350% +$646K 0.17% 79
2021
Q1 		$200K Hold
667
– – 0.05% 138
2020
Q4 		$170K Hold
667
– – 0.06% 132
2020
Q3 		$166K Hold
667
– – 0.04% 145
2020
Q2 		$232K Sell
667
-358
-35% -$112K 0.05% 160
2020
Q1 		$275K Sell
1,025
-140
-12% -$43.3K 0.05% 171
2019
Q4 		$377K Buy
+1,165
New +$338K 0.03% 221

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Nexpoint Asset Management's NKTR Position: Q4 2021 in Review

Nexpoint Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 2,667 shares — an estimated $718K sold.

Nexpoint Asset Management first reported a position in NKTR in Q4 2019 and held it in 8 quarters. The position peaked at $772K in Q2 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Nexpoint Asset Management reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Nexpoint Asset Management sold 2,667 Nektar Therapeutics shares in Q4 2021, an estimated $718K.
  • Nexpoint Asset Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 8 quarters.
  • Nexpoint Asset Management's Nektar Therapeutics position peaked at $772K in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Nexpoint Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.